Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 20/20 | 0.37 |
| ▸ | WNT1 | P04628 | 12/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | CLK3 | P49761 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548485 | 0.90 | DYRK1A (0.42) | GSK3BDYRK1AWNT1 | |
| SCHEMBL2548488 | 0.90 | DYRK1A (0.42) | GSK3BDYRK1AWNT1 | |
| SCHEMBL1742951 | 0.85 | GSK3B (0.42) | GSK3BDYRK1AWNT1 | |
| SCHEMBL1743842 | 0.82 | AKT1 (0.36) | GSK3BDYRK1A | |
| SCHEMBL1744902 | 0.81 | ATM (0.32) | GSK3BDYRK1A | |
| SCHEMBL1743902 | 0.80 | GSK3B (0.30) | GSK3BDYRK1A | |
| SCHEMBL1742991 | 0.78 | AAK1 (0.31) | GSK3BDYRK1A | |
| SCHEMBL2546675 | 0.78 | CDK2 (0.32) | GSK3BDYRK1A | |
| SCHEMBL2541336 | 0.77 | FPR3 (0.34) | — | |
| SCHEMBL2541340 | 0.77 | FPR3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | GSK3B 145/4885DYRK1A 2916/4885WNT1 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.